Mid-life: a critical window for intervention during aging

Published: Jan. 14, 2025

Mid-life represents a pivotal period marked by profound physiological and metabolic transitions, increasing susceptibility to chronic diseases. This review explores the molecular systemic underpinnings of mid-life transition integrating insights from recent studies that elucidate aging-associated changes in plasma proteome, immune system, adipose tissue remodeling, cellular senescence. Nonlinear waves proteomic alterations have been identified as critical transitions inflammatory hormonal pathways. In addition, sex-specific aging trajectories linked adaptive immunity decline innate activation vulnerabilities mid-life. Moreover, tissue’s central role has established its early remodeling cytokine secretion drive stress. Furthermore, Glb1-2A-mCherry reporter introduced monitor aging, identifying crucial phase for cardiac hypertrophy senescence-induced inflammation. Collectively, these findings our understanding underscoring interplay between processes health, with emerging window intervention. also underscores biomarkers therapeutic strategies alleviate challenges mid-life, thereby promoting healthy aging.

Language: Английский

---

Postmarketing safety of [ ¹⁷⁷ Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system

Expert Opinion on Drug Safety, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 11, 2025

[177Lu]Lu-PSMA-617 (Pluvicto), a new radioligand therapy that targets prostate-specific membrane antigen (PSMA), has been approved to treat metastatic castration-resistant prostate cancer (mCRPC). However, the real-world safety profile of not systemically evaluated. Adverse event reports for were retrieved from April 2022 June 2024 The Food and Drug Administration Event Reporting System (FAERS) database. Disproportionality analysis was conducted by four algorithms: reporting odds ratio (ROR), proportional (PRR), Multi-Item Gamma Poisson Shrinker (MGPS) Bayesian Confidence Propagation Neural Network (BCPNN). Subgroup analysis, time-to-onset sensitivity also employed. 384,2712 adverse retrieved, which 870 associated with in patients. We identified known events (fatigue/asthenia, anemia, thrombocytopenia nausea) discovered specified on label (loss libido, hydronephrosis, supraventricular tachycardia, tumor lysis syndrome, flare). revealed high-risk signals included stomatitis, pneumonia, leukopenia, sepsis patients aged over 85. median onset time 55 days (interquartile range 24-124 days). findings provide insights into valuable references clinical applications mCRPC.

Language: Английский

---

Evaluation of Anti-aging Agents Using the D-Galactose-Induced Accelerated Aging Model

Methods in molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Chronic Inflammation Linking Atherosclerosis to Cognitive Impairment: Multi-Target Mechanisms and Therapeutic Advances in Chinese Herbal Medicine

Brain Behavior and Immunity Integrative, Journal Year: 2025, Volume and Issue: unknown, P. 100122 - 100122

Published: April 1, 2025

Language: Английский

---

Frontiers in Age-Related Diseases and Nutritional Interventions

Nutrients, Journal Year: 2025, Volume and Issue: 17(10), P. 1658 - 1658

Published: May 13, 2025

The aging population presents one of the greatest challenges to sustainable development, progressing at an unprecedented rate in recent years [...]

Language: Английский

---